Centre Hospitalier De La Cote Basque

At Centre Hospitalier De La Cote Basque in Bayonne, much of the clinical research focuses on Hemic and Lymphatic Diseases and Neoplasms, especially acute myeloid leukemia, myelodysplastic syndrome, diffuse large B-cell lymphoma, and multiple myeloma. These studies are designed to test new treatment strategies, improve disease control, and support better outcomes for people with hard-to-treat blood cancers.

• Research in acute myeloid leukemia and myelodysplastic syndrome explores new approaches for newly diagnosed and older patients.
• Trials in diffuse large B-cell lymphoma and related lymphomas aim to improve response rates and extend progression-free survival.
• Studies in multiple myeloma and other hematologic cancers assess whether newer therapies can work better than current standards.

This active hematology program brings together multiple investigators and a broad range of blood cancer studies, reflecting a strong focus on advancing treatment options for complex hematologic malignancies.

The site also conducts extensive research in breast cancer and other solid tumors, including prostate cancer, lung cancer, melanoma, and hepatocellular carcinoma. These trials are largely aimed at evaluating new combinations, improving disease-free survival, and delaying progression in patients with advanced or high-risk disease.

• Studies in HER2-positive and triple negative breast cancer examine better ways to reduce recurrence and improve long-term control.
• Research in metastatic non-small cell lung cancer and melanoma focuses on improving effectiveness of modern cancer therapies.
• Trials in prostate cancer, hepatocellular carcinoma, and small bowel adenocarcinoma look for more effective treatment strategies in advanced disease.

These oncology studies reflect a broad commitment to testing innovative cancer treatments across several major tumor types at Centre Hospitalier De La Cote Basque.

Another important area of research involves Cardiovascular Diseases, especially atrial fibrillation and the prevention of stroke and systemic embolism. The trials in this field are evaluating whether newer blood-thinning treatments can match or improve current options while maintaining safety.

• Studies in atrial fibrillation assess better ways to prevent stroke and other serious clot-related events.
• Research on thromboprophylaxis in cancer patients aims to reduce the risk of venous thromboembolism during treatment.
• These projects compare treatment effectiveness and safety in people at increased cardiovascular or clotting risk.

This portfolio connects cardiovascular medicine with cancer care, showing interest in both prevention and safer treatment support for patients with complex conditions.

The research program also includes Digestive System Diseases and Immune system processes, with attention to cancers and conditions affecting the liver, colon, and upper digestive tract. These trials are aimed at improving treatment effectiveness, refining disease monitoring, and supporting better control of cancer progression.

• Studies in hepatocellular carcinoma, colon carcinoma, and small bowel adenocarcinoma evaluate new treatment approaches for digestive cancers.
• Work involving immune-based cancer therapies looks at how the body’s immune response can be used more effectively against tumors.
• Some trials explore whether treatment can be tailored more precisely for patients with advanced disease or signs of relapse.

Overall, this area highlights the site’s interest in gastrointestinal oncology and immunotherapy, with research designed to improve outcomes in difficult-to-treat cancers.